AssureCKD and University of Manitoba Enter Sponsored Research Agreement to Advance Next-Generation Kidney Screening & Diagnostic Technology
AssureCKD, a Canadian medical device company developing point-of-care solutions for chronic kidney disease (CKD) detection, today announced it has signed a two-year Sponsored Research Agreement (SRA) with the University of Manitoba, effective January 1, 2025.
The collaboration will be led by Dr. Francis Lin, Professor in the Faculty of Science, whose expertise in microfluidic devices, cell biology, and immunology is central to the project’s objectives. Under the agreement, Dr. Lin and his research team will work alongside AssureCKD to develop and refine key components of the company’s MATLOC diagnostic platform.
The research program will focus on three core areas:
Microfluidic development for measuring multiple urine and blood biomarkers relevant to CKD screening and diagnosis.
Design and optimization of a portable optical reader to enable rapid, point-of-care analysis.
Integration of a connected smartphone application for seamless data transfer, reporting, and clinical decision support.
“This agreement builds on a decade of scientific collaboration and represents a critical step in translating innovative lab research into a clinically deployable solution,” said Harrison Ross, CEO of AssureCKD. “Working closely with Dr. Lin’s team will accelerate our progress toward making early CKD detection accessible in primary care and community health settings.”
The two-year partnership underscores the company’s commitment to pairing cutting-edge academic research with commercial expertise to address the significant unmet need in CKD screening, affecting an estimated 120+ million at-risk individuals in the United States alone.
About AssureCKD
AssureCKD is developing MATLOC, a lab-equivalent diagnostic platform designed to screen, diagnose, and monitor chronic kidney disease at the point-of-care. By enabling rapid, accessible, and cost-effective testing in primary care and decentralized settings, AssureCKD aims to increase screening rates and facilitate earlier intervention, ultimately improving outcomes and reducing expensive healthcare costs.